"Information on cefmenoxime overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions."@en . . . "(6R,7R)-7-[[(2e)-2-(2-amino-1,3-Thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (iupac)"@en . . "# Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T: [Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis] Jpn J Antibiot. 1995 May;48(5):602-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7637194 # Paladino JA, Fell RE: Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother. 1994 Mar;28(3):384-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8193431 # Duncker GI, Reich U, Krausse R: Cefmenoxime in corneal organ culture. Ophthalmologica. 1994;208(5):262-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7816419 # Tsuchiya K, Kondo M, Kida M, Nakao M, Iwahi T, Nishi T, Noji Y, Takeuchi M, Nozaki Y: Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1981 Jan;19(1):56-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6941742"@en . "approved"@en . . . . . . . . . . . . . . "1 hour"@en . . "Cefmenoxima"@en . . . . "Enteric bacteria and other eubacteria"@en . "The bactericidal activity of cefmenoxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefmenoxime is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases."@en . . "(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure"@en . . . . . . . "Bioavailability is approximately 100% following intramuscular injection."@en . "Yasushi Morita, \"Method for preventing coloration of aqueous preparations of cefmenoxime.\" U.S. Patent US4808577, issued November, 1985."@en . "Cefmenoximum"@en . "Cefmenoxime"@en . " "@en . " "@en . "Used to treat female gynecologic and obstetric infections caused by susceptible aerobic (including the gonococcus) and anaerobic bacteria."@en . . . "Cefmenoxime is a third-generation cephalosporin antibiotic. [Wikipedia]"@en . . . "50-70%"@en . . . . "65085-01-0"@en . . . . .